Biology of Pellino1: a potential therapeutic target for inflammation in diseases and cancers

Front Immunol. 2023 Dec 18:14:1292022. doi: 10.3389/fimmu.2023.1292022. eCollection 2023.

Abstract

Pellino1 (Peli1) is a highly conserved E3 Ub ligase that exerts its biological functions by mediating target protein ubiquitination. Extensive evidence has demonstrated the crucial role of Peli1 in regulating inflammation by modulating various receptor signaling pathways, including interleukin-1 receptors, Toll-like receptors, nuclear factor-κB, mitogen-activated protein kinase, and phosphoinositide 3-kinase/AKT pathways. Peli1 has been implicated in the development of several diseases by influencing inflammation, apoptosis, necrosis, pyroptosis, autophagy, DNA damage repair, and glycolysis. Peli1 is a risk factor for most cancers, including breast cancer, lung cancer, and lymphoma. Conversely, Peli1 protects against herpes simplex virus infection, systemic lupus erythematosus, esophageal cancer, and toxic epidermolysis bullosa. Therefore, Peli1 is a potential therapeutic target that warrants further investigation. This comprehensive review summarizes the target proteins of Peli1, delineates their involvement in major signaling pathways and biological processes, explores their role in diseases, and discusses the potential clinical applications of Peli1-targeted therapy, highlighting the therapeutic prospects of Peli1 in various diseases.

Keywords: IL-1R/TLRs; NF-κB; Peli1; cancer; immune; inflammation; ubiquitination.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Inflammation / metabolism
  • Neoplasms* / drug therapy
  • Nuclear Proteins* / metabolism
  • Phosphatidylinositol 3-Kinases
  • Ubiquitin-Protein Ligases / metabolism

Substances

  • Nuclear Proteins
  • Phosphatidylinositol 3-Kinases
  • Ubiquitin-Protein Ligases

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by the Outstanding Scientific Fund Q18 of the Shengjing Hospital (to JF) and the National Natural Science Foundation of China (No. 82271275 to JF).